Pacira BioSciences (PCRX) Total Current Liabilities (2010 - 2026)

Pacira BioSciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 65.44% year-over-year to $108.8 million in Q1 2026; TTM through Mar 2026 was $108.8 million, a 65.44% decrease from a year earlier, with the FY2025 full-year figure at $120.6 million, down 61.09% from the prior year.
• Total Current Liabilities slipped to $108.8 million in Q1 2026 per PCRX's latest filing, from $120.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $314.7 million in Q1 2025 and bottomed at $92.7 million in Q2 2024.
• The 5-year median for Total Current Liabilities is $120.6 million (2025), against an average of $169.6 million.
• Across the five-year window, Total Current Liabilities tumbled 71.64% in 2022 and jumped 237.86% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $147.8 million in 2022, then tumbled by 34.1% to $97.4 million in 2023, then surged by 218.25% to $309.9 million in 2024, then sank by 61.09% to $120.6 million in 2025, then decreased by 9.79% to $108.8 million in 2026.
• Per Business Quant, the three latest PCRX Total Current Liabilities figures stand at $108.8 million (Q1 2026), $120.6 million (Q4 2025), and $107.1 million (Q3 2025).